ArticleHepatology (Baltimore, Md.)2017
FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients.
Article in Hepatology (Baltimore, Md.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Review
- FIB-4 Index as a Non-Invasive Biomarker of Congestion and Prognosis in Heart Failure.Journal of clinical medicine · 2026Review
- Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: mechanisms and clinical implications from a heart-liver metabolic axis perspective.Frontiers in pharmacology · 2026Review
- Association of liver fibrosis scores with all-cause and cardiovascular mortality in patients with heart failure.Clinical and translational science · 2024Article
- Explainable machine learning model for predicting the risk of significant liver fibrosis in patients with diabetic retinopathy.BMC medical informatics and decision making · 2024Article
- Article
- Association Between End-Stage Liver Disease and Incident Heart Failure in an Integrated Health System.Journal of general internal medicine · 2023Article
- Liver fibrosis scores and atrial fibrillation incidence in heart failure with preserved ejection fraction.ESC heart failure · 2022Article
- Clinical Spectrum of Nonalcoholic Fatty Liver Disease in Patients with Chronic Obstructive Pulmonary Disease.Turkish thoracic journal · 2022Article
- Circulating MicroRNAs as a Tool for Diagnosis of Liver Disease Progression in People Living with HIV-1.Viruses · 2022Review
- Markers of Monocyte Activation, Inflammation, and Microbial Translocation Are Associated with Liver Fibrosis in Alcohol Use Disorder.Journal of clinical medicine · 2021Article
- Assessment of liver disease in patients with chronic hepatitis C and unhealthy alcohol use.World journal of gastroenterology · 2021Review
- FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic.Life (Basel, Switzerland) · 2021Review
- Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction.Scientific reports · 2020Article
- HIV and cardiovascular disease.The lancet. HIV · 2020Review
- Heart Failure among People with HIV: Evolving Risks, Mechanisms, and Preventive Considerations.Current HIV/AIDS reports · 2019Review
- Liver stiffness and arterial stiffness/abnormal central hemodynamics in the early stage of heart failure.International journal of cardiology. Heart & vasculature · 2018Article
- HIV and Cardiovascular Disease: Update on Clinical Events, Special Populations, and Novel Biomarkers.Current HIV/AIDS reports · 2018Review
- FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C.Progress in cardiovascular diseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 11 institutions in 2 countries.
Funding
Abstract
Liver fibrosis is common, particularly in individuals who are infected with human immunodeficiency virus (HIV). HIV-infected individuals have excess congestive heart failure (CHF) risk compared with uninfected people. It remains unknown whether liver fibrosis stage influences the CHF risk or if HIV or hepatitis C virus (HCV) infection modifies this association. Our objectives were to assess whether 1) stage of liver fibrosis is independently associated with incident CHF and 2) the association between stage of liver fibrosis and incident CHF is modified by HIV/HCV status. Participants alive on or after April 1, 2003, in the Veterans Aging Cohort Study were included. Those without prevalent cardiovascular disease were followed until their first CHF event, death, last follow-up date, or December 31, 2011. Liver fibrosis was measured using the fibrosis 4 index (FIB-4), which is calculated using age, aminotransferases, and platelets. Cox proportional hazards regression models were adjusted for cardiovascular disease risk factors. Among 96,373 participants over 6.9 years, 3844 incident CHF events occurred. FIB-4 between 1.45 and 3.25 (moderate fibrosis) and FIB-4 > 3.25 (advanced fibrosis/cirrhosis) were associated with CHF (hazard ratio [95% confidence interval], 1.17 [1.07-1.27] and 1.65 [1.43-1.92], respectively). The association of advanced fibrosis/cirrhosis and incident CHF persisted regardless of HIV/HCV status.
conclusionModerate and advanced liver fibrosis/cirrhosis are associated with an increased risk of CHF. The association for advanced fibrosis/cirrhosis persists even among participants without hepatitis C and/or HIV infection. Assessing liver health may be important for reducing the risk of future CHF events, particularly among HIV and hepatitis C infected people among whom cardiovascular disease risk is elevated and liver disease is common. (Hepatology 2017;66:1286-1295).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.